The Senate Health, Education, Labor, and Pensions (HELP) Committee Chair Bill Cassidy, MD (R-La.) continued his yearslong inquiry into the 340B Drug Pricing Program with a Feb. 1 letter requesting additional information about the role of Apexus (PDF) in the program. Per Cassidy’s letter, Apexus has served as the 340B prime vendor since 2004 and is charged with negotiating sub-340B pricing on behalf of covered entities, “establishing distribution solutions and networks that improve access to affordable medications,” and providing “value-added products and services,” such as educational materials and technical assistance. The letter requested additional information about Apexus’ revenue model, business practices, organizational structure, and relationship with its parent company.
This letter builds on Cassidy’s ongoing investigation into the 340B program, following prior inquiries sent to hospitals, federally qualified health centers, contract pharmacies, and pharmaceutical manufacturers. Cassidy released the initial findings from the responses he received in a report entitled Congress Must Act to Bring Needed Reforms to the 340B Drug Pricing Program [refer to Washington Highlights, April 25, 2025].
- Washington Highlights